NCT05279872View on ClinicalTrials.gov

A Study of Zanubrutinib in Patients With ITP

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions
Immune ThrombocytopeniaBruton Tyrosine Kinase
Interventions
DRUG

Zanubrutinib

Zanubrutinib 80mg po qd 6 weeks

Trial Locations (1)

100010

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT05279872 - A Study of Zanubrutinib in Patients With ITP | Biotech Hunter | Biotech Hunter